Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
IBO
Impact BioMedical Inc.
Impact BioMedical Inc. (IBO) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.3
/ 5.0
C
Value
C-
Factor Score
1.9
/ 5.0
Growth
C
Factor Score
2.5
/ 5.0
Profitability
C+
Factor Score
2.6
/ 5.0
Momentum
D+
Factor Score
1.7
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.4
EV / EBITDA
-9.6
Rev Growth YoY
16.7%
Gross Margin
0.0%
Price Return 3M
-22.8%
Price Return 12M
-39.3%
Catalyst Signal
0.00
Market Cap
$37.2M
TTM Revenue
$38.0K
Price / Sales
977.7
ROE
71.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C- (1.9) | C (2.5) | C+ (2.6) | D+ (1.7) | C+ (2.6) | C (2.3) |
| 2026-11-05 | C- (1.9) | F (0.5) | C- (1.9) | D+ (1.7) | C+ (2.7) | D+ (1.7) |
| 2026-10-29 | C- (1.9) | F (0.5) | C- (1.9) | D+ (1.8) | C+ (2.7) | D+ (1.8) |
| 2026-10-22 | C- (1.9) | F (0.5) | C- (1.9) | C- (2.0) | C+ (2.6) | D+ (1.8) |
| 2026-10-15 | C- (1.9) | F (0.5) | C- (1.9) | D+ (1.7) | C+ (2.6) | D+ (1.7) |
Page
1
of
3